Skip to main content

Table 2 Subgroup analysis of overall survival from available data

From: Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials

Subgroup No. of studies OS HR (95 % CI)d Weight (%) Heterogeneity within subgroup
Criteria Characteristics I 2 (%) p value
Experimental drug Azacitidinea 3 0.67 (0.56, 0.79) 48.3 0 0.38
Decitabine 2 0.86 (0.73, 1.02) 51.7 0 0.85
Subgroup difference p = 0.04*
Cytogenetics riskb Poor risk 3 0.75 (0.56, 1.00) 43.9 26 0.26
Intermediate risk 3 0.78 (0.40, 1.52) 37.0 65 0.06
Good risk 2 0.63 (0.42, 0.93) 19.0 0 0.64
Subgroup difference p = 0.75
BM blast countc More than 30 % 2 0.79 (0.68, 0.92) 48.9 0 0.32
Less than 30 % 3 0.82 (0.57, 1.18) 51.1 74 0.02
Subgroup difference p = 0.85
Conventional care regimens BSC only 2 0.76 (0.53, 1.10) 28.4 44 0.18
BSC and CTxe 3 0.73 (0.60, 0.90) 71.6 53 0.12
Subgroup difference p = 0.85
  1. aOne study [25, 30] included only RAEB and RAEB-T for the HR analysis of OS
  2. bTwo studies [30, 32] did not report subgroup survival outcome data according to cytogenetic risk
  3. cOne study [30] did not report subgroup survival outcome data according to BM blast count (≥30 vs. <30 %)
  4. dHR value was extracted from subgroup analysis data of individual trial
  5. eCTx includes low dose cytarabine and intensive chemotherapy
  6. *Statistically significant